Abstract
A synergism between cis-platinum (CDDP) and radiotherapy (RT) has been demonstrated both in culture systems and in clinical studies. On the above basis, we planned, in patients with locally advanced or unresectable squamous cell carcinoma of the head and neck, a concomitant treatment with CDDP 80 mg/m2 i.v. every 3 weeks for three doses (days 1.21 and 42) and RT in the primary and in the neck nodes bilaterally, fora total dose of 60-70 Gy. Thirty-five untreated patients with poor prognosis unresectable stage II and stages 111-IV disease were entered in the study and 32 were evaluable. Complete response (CR) rate was 75% (24/32) with 95% confidence limits from 60 to 90% (±15%); 8 cases (25%) achieved a partial response, for an overall response rate of 100%. A significantly higher CR rate and a longer survival rate was observed in patients with good performance status (PS=90-100) and stages II-III. The overall estimated 2-year survival is 46%; 59% for patients who obtained a CR versus 0% for those who achieved only a partial response. Overall the treatment was well tolerated and gastrointestinal and hematologic toxicides were the most common side effects. In conclusion, the combination of CDDP plus RT is a very effective and safe treatment and we recommend such an approach in head and neck squamous cell carcinoma, particularly in those patients with good PS and with unresectable stage II or stage III disease.
| Original language | English |
|---|---|
| Pages (from-to) | 270-276 |
| Number of pages | 7 |
| Journal | Oncology |
| Volume | 48 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1991 |
Fingerprint
Keywords
- Cis-platinum
- Combined treatment
- Head and neck cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck. / Gasparini, Giampietro; Pozza, Franco; Reciter, Gianfranco; Panizzoni, Gino Antonio; Cristoferi, Valentina; Squaquara, Roberto; Dal Fior, Sandro.
In: Oncology, Vol. 48, No. 4, 1991, p. 270-276.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck
AU - Gasparini, Giampietro
AU - Pozza, Franco
AU - Reciter, Gianfranco
AU - Panizzoni, Gino Antonio
AU - Cristoferi, Valentina
AU - Squaquara, Roberto
AU - Dal Fior, Sandro
PY - 1991
Y1 - 1991
N2 - A synergism between cis-platinum (CDDP) and radiotherapy (RT) has been demonstrated both in culture systems and in clinical studies. On the above basis, we planned, in patients with locally advanced or unresectable squamous cell carcinoma of the head and neck, a concomitant treatment with CDDP 80 mg/m2 i.v. every 3 weeks for three doses (days 1.21 and 42) and RT in the primary and in the neck nodes bilaterally, fora total dose of 60-70 Gy. Thirty-five untreated patients with poor prognosis unresectable stage II and stages 111-IV disease were entered in the study and 32 were evaluable. Complete response (CR) rate was 75% (24/32) with 95% confidence limits from 60 to 90% (±15%); 8 cases (25%) achieved a partial response, for an overall response rate of 100%. A significantly higher CR rate and a longer survival rate was observed in patients with good performance status (PS=90-100) and stages II-III. The overall estimated 2-year survival is 46%; 59% for patients who obtained a CR versus 0% for those who achieved only a partial response. Overall the treatment was well tolerated and gastrointestinal and hematologic toxicides were the most common side effects. In conclusion, the combination of CDDP plus RT is a very effective and safe treatment and we recommend such an approach in head and neck squamous cell carcinoma, particularly in those patients with good PS and with unresectable stage II or stage III disease.
AB - A synergism between cis-platinum (CDDP) and radiotherapy (RT) has been demonstrated both in culture systems and in clinical studies. On the above basis, we planned, in patients with locally advanced or unresectable squamous cell carcinoma of the head and neck, a concomitant treatment with CDDP 80 mg/m2 i.v. every 3 weeks for three doses (days 1.21 and 42) and RT in the primary and in the neck nodes bilaterally, fora total dose of 60-70 Gy. Thirty-five untreated patients with poor prognosis unresectable stage II and stages 111-IV disease were entered in the study and 32 were evaluable. Complete response (CR) rate was 75% (24/32) with 95% confidence limits from 60 to 90% (±15%); 8 cases (25%) achieved a partial response, for an overall response rate of 100%. A significantly higher CR rate and a longer survival rate was observed in patients with good performance status (PS=90-100) and stages II-III. The overall estimated 2-year survival is 46%; 59% for patients who obtained a CR versus 0% for those who achieved only a partial response. Overall the treatment was well tolerated and gastrointestinal and hematologic toxicides were the most common side effects. In conclusion, the combination of CDDP plus RT is a very effective and safe treatment and we recommend such an approach in head and neck squamous cell carcinoma, particularly in those patients with good PS and with unresectable stage II or stage III disease.
KW - Cis-platinum
KW - Combined treatment
KW - Head and neck cancer
UR - http://www.scopus.com/inward/record.url?scp=0025878879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025878879&partnerID=8YFLogxK
U2 - 10.1159/000226941
DO - 10.1159/000226941
M3 - Article
C2 - 1891167
AN - SCOPUS:0025878879
VL - 48
SP - 270
EP - 276
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 4
ER -